Hung Trinh: iNKT Cells at the Interplay Between Innate and Adaptive Immune Responses
Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn about a paper by Benjamin Garmezy et al. published in Oncogene:
“A remarkable work, Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
Invariant natural killer T (iNKT) cells, previously considered to be tissue-resident, are an emerging and versatile allogeneic cell therapy with potent anti-tumor activity, acting at the interplay between innate and adaptive immune responses.
We report an unprecedented complete remission in a heavily pre-treated metastatic germ cell neoplasm, using ex vivo expanded allogeneic iNKT cells, warranting further trials.”
Title: Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor
Authors: Benjamin Garmezy, Joseph E. Grossman, Jennifer Buell, Thiago Favano, Justin Stebbing, Steven O’Day, Marco A. Purbhoo, Dhan Chand, F. Anthony Greco
You can read the Full Article in Oncogene.
More posts featuring Hung Trinh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023